-Live Mint Tariffs reach at least Rs.4 per unit in many states, finds analysis, amid efforts to bail out state discoms Indian domestic consumers in 16 states are paying at least `4 per unit for power and in some cases even more, according to an analysis, thus giving the lie to the long-held axiom that raising tariffs is nearly impossible in India given the political compulsions. The finding also shows conclusively that...
More »SEARCH RESULT
Total Matching Records found : 3986
A slew of schemes for slum dwellers
-The Hindu Jaipur: Slum dwellers in Jaipur will shortly get the benefit of a slew of schemes with the selection of the Rajasthan Capital in the National Urban Livelihood Mission. The Rajiv Awas Yojana will also be implemented here from next month for construction of houses for them. Jaipur Mayor Jyoti Khandelwal announced at a discourse on "Urban poverty and strengthening of civil society voices" here on Thursday that special measures would...
More »EU, Australia, Canada may follow India’s Patent Law -Divya Rajagopal
-The Economic Times MUMBAI: India's strong stance on minor drug innovations could reverberate in national parliaments and courthouses of the developed world as Australia, the EU and Canada get ready to discuss and ban patent protection for frivolous improvements. A top Australian government body on Wednesday asked for changes in its patent laws relating to drugs saying that the indiscriminate grant of patents to incremental innovations should be checked and that...
More »Novartis patent case: Glivec developer Brian Druker hails SC ruling- Chidanand Rajghatta
-The Economic Times WASHINGTON: Big Pharma found little support from the small guy on the street as the Indian Supreme Court's decision to reject patent claims of the drug maker Novartis for its celebrated cancer medicine Glivec reverberated across the world. The pharma lobby railed against the decision but the overwhelming sentiment, from physicians to politicians, from academia to media, particularly in a country groaning from the high cost of health care,...
More »Calling big pharma’s bluff -Dwijen Rangnekar
-The Hindu The lesson from the Supreme Court ruling on Gleevec is that pharmaceutical multinational corporations need to focus research on genuine innovations rather than on ways to evergreen their patents The much awaited Supreme Court judgment on Gleevec has been delivered. Novartis has failed in reversing the rejection of its patent. And, predictably - like a scratched record - there have been suggestions that pharma investments in India will dry...
More »
